The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease. - Wikidata - wikimedia - TriplyDB

The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease.

The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease.

http://www.wikidata.org/entity/Q36252668

about

Use of Benzodiazepines in Alzheimer's Disease: A Systematic Review of Literature Delirium in the elderly: Current problems with increasing geriatric age Nurse-Led Medicines' Monitoring for Patients with Dementia in Care Homes: A Pragmatic Cohort Stepped Wedge Cluster Randomised Trial Psychotropic medications and the transition into care: a national data linkage study.Antipsychotic prescribing for Alzheimer's disease and related disorders in specialized settings from 2010 to 2014 in France: a repeated cross-sectional study.Chronic diazepam administration increases the expression of Lcn2 in the CNS.Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.The Cache County Study on Memory in Aging: factors affecting risk of Alzheimer's disease and its progression after onset Effect of medications on physical function and cognition in nursing home residents with dementia Plasma prion protein concentration and progression of Alzheimer disease.The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease.Posterior Teeth Occlusion Associated with Cognitive Function in Nursing Home Older Residents: A Cross-Sectional Observational Study Antidepressant Use and Cognitive Decline: The Health and Retirement Study The association of antidepressant drug usage with cognitive impairment or dementia, including Alzheimer disease: A systematic review and meta-analysis.Neuropsychiatric Symptoms Predict Functional Status in Alzheimer's Disease.Mortality and use of psychotropic medication in patients with stroke: a population-wide, register-based study Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease.Improving the management of behaviour that challenges associated with dementia in care homes: protocol for pharmacy-health psychology intervention feasibility study.Pharmacotherapeutic management of dementia across settings of care.Clinicopathological correlates of depression in early Alzheimer's disease in the NACC.Vascular risk factors and neuropsychiatric symptoms in Alzheimer's disease: the Cache County Study.Inequalities in receipt of mental and physical healthcare in people with dementia in the UK.The new DSM-5 diagnosis of mild neurocognitive disorder and its relation to research in mild cognitive impairment.Biochemical and Radiological Markers of Alzheimer's Disease Progression.Serotonergic drugs for the treatment of neuropsychiatric symptoms in dementia.Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E.Multidimensional assessment of challenging behaviors in advanced stages of dementia in nursing homes-The insideDEM framework.Predictive factors for dementia and cognitive impairment among residents living in the veterans' retirement communities in Taiwan: Implications for cognitive health promotion activities.Racial and ethnic differences in psychotropic medication use among community-dwelling persons with dementia in the United States.Benzodiazepine Misuse in the Elderly: Risk Factors, Consequences, and Management.Individualized formulation-led interventions for analyzing and managing challenging behavior of people with dementia - an integrative review.Neuropsychiatric symptoms in people screened positive for dementia in primary care.Management of Behavioral and Psychological Symptoms of Dementia.Anticholinergic Drug Use and Risk to Cognitive Performance in Older Adults with Questionable Cognitive Impairment: A Cross-Sectional Analysis.Do antipsychotics lead to cognitive impairment in dementia? A meta-analysis of randomised placebo-controlled trials.A cross-sectional examination of the prevalence of psychotropic medications for people living with dementia in Australian long-term care facilities: issues of concern.Influence of central nervous system-acting drugs on results of cognitive testing in geriatric inpatients.Medication Profiles of Patients with Cognitive Impairment and High Anticholinergic Burden.Evolution of the Antidepressant Prescribing in Alzheimer's Disease and Related Disorders Between 2010 and 2014: Results from the French National Database on Alzheimer's Disease (BNA).Person-Centered Primary Care Strategies for Assessment of and Intervention for Aggressive Behaviors in Dementia.

P2860

Q27001758-E98E2C27-20EE-42D7-96DA-19695E08AD07 Q28070106-E4486AD1-FCDD-4211-8903-347261CE45BD Q28550194-2ED222EB-304F-44FE-848C-F2DC91187177 Q30586082-DF03E99A-D51D-4E0C-8A25-6D3D3092C8E6 Q33604532-8227BF0B-3AC4-4778-9460-68B38B607C91 Q33771399-10431D16-3AAB-4343-8714-CD88A46F1EA2 Q33863623-9B5347D2-5080-462F-A775-5444B06BC0EA Q33873941-E77783EF-F2C8-472E-A9BA-8959BD4163F7 Q34103934-01E8CD35-BE41-4F52-85E6-CDD51371724B Q34307247-8F419116-A7EC-4B95-BD84-3EBA4ADA7EE8 Q35119259-CF1ABF46-B278-4A78-AA21-3278ABA42C6E Q35825889-995A805B-9F90-4071-8402-7DE35732FB8A Q36201714-6FCFEA31-8DB1-46FF-A6C1-346762BD4E7D Q36234470-09753777-E608-4213-9D95-B263BB1FE56E Q36573027-F5E8E0CE-9A1E-4E47-ACD8-ED498CEB0258 Q36670523-DE58D4DA-E020-4D5B-B235-03725CA7DD5A Q36724965-8133177C-B2FD-4C62-BB3F-9BBF251C893E Q36732899-119DC2D5-131A-43A0-8E67-0523FD4B2A33 Q36849968-F6064B51-5C44-4616-BF17-AB2C6B7B5F0F Q37172387-31FBA454-E9E6-40E8-AC20-0537BE090B04 Q37445941-7DF6928D-0F8F-43A5-A901-6503773F9BDE Q37735666-682AB0BB-F4C6-47F2-80AA-04901134FA49 Q38219079-A2A6AAB5-15C6-46BA-8BC6-93659EB0AEE7 Q38693438-F584C704-3E99-4680-B2EB-BE40C75350E3 Q38737187-734676BC-BEEB-4513-8216-99516927FB44 Q38754916-FB294049-04E5-4887-9430-173CCD376765 Q38809852-8B02A113-8C3D-4C06-B073-B419AA0C14F4 Q38823686-54AC5205-7128-40C6-9054-630C3769BABE Q38914588-1455A23E-CECD-4183-B89A-8E3044C31ABA Q38934261-036D225B-FE8E-4EDE-9CFC-DC89C4CE3BC9 Q38997431-9660CD67-4C55-4743-AB9D-FED6E7B84553 Q39124692-62252AEC-0B24-4C28-B104-976BCCDDE3D4 Q39209888-EBE03D9C-CBBF-46DD-8210-5FCB4C977EA3 Q39379518-D023350D-C981-4356-A46A-6FADE4CBC3AD Q39485229-9DCD0759-3FDC-4226-8C8B-F6FC776F4B19 Q47378955-B9C116D9-73B0-43D8-82AD-80DE6867C209 Q47834444-0F0C6B90-79A8-4CF0-87B9-34FCE126AE58 Q48100680-1EE37F65-6ABF-4DBA-BA3D-1E6E6EE23D31 Q50637315-5E181662-FF37-4FB7-A56C-143C1D4B352F Q52737754-076BDC88-347B-4E80-9193-1B04F1790251

P2860

The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease.

http://www.wikidata.org/entity/Q36252668

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

The association of psychotropi ...... ectory of Alzheimer's disease.

@ast

The association of psychotropi ...... ectory of Alzheimer's disease.

@en

type

label

The association of psychotropi ...... ectory of Alzheimer's disease.

@ast

The association of psychotropi ...... ectory of Alzheimer's disease.

@en

prefLabel

The association of psychotropi ...... ectory of Alzheimer's disease.

@ast

The association of psychotropi ...... ectory of Alzheimer's disease.

@en

P1433

Q36252668-AF634F79-CD0E-4F14-9242-F373FB4764DB

P1476

Q36252668-94FB2721-BBB6-4D1B-A18E-D0E46CADCF2E

P2093

Q36252668-104FB477-C157-4D44-A318-6CF866692C4B

Q36252668-19814433-6827-49D5-AD89-FF0DC3EF32BF

Q36252668-290B12F5-951D-42BF-A8E8-F2EC5524796E

Q36252668-2EC0867E-37A8-47CF-B054-74D42BD04247

Q36252668-5355F669-F95D-4658-94DD-8942A9EBC0D8

Q36252668-5FC0C24E-6236-4E56-B5C7-459A224F4E42

Q36252668-64253A90-6C3F-427F-AFC6-5812065E4032

Q36252668-69994CF1-9303-4B3F-B04D-3FA0583189EF

Q36252668-728832A9-3D7F-43F1-A9D4-602FE05465FD

Q36252668-7EDAB539-3128-4735-9DD7-7D5969E13EB1

P2860

Q36252668-00EE5EE9-25CC-4058-8B37-F2DB24BC8A06

Q36252668-0640158F-F9FE-49C6-B83F-30C2C80D4CF2

Q36252668-099CD7D2-FC98-4EBF-84B4-3E6D835DF782

Q36252668-1681CAA5-5940-4D87-8FDF-20D634F338A2

Q36252668-1D4F48AF-B674-4F82-A787-4BA7C3637684

Q36252668-2FB7EBE3-4E3B-45A8-9591-688DDFD6C9BE

Q36252668-3D428C09-ECD3-4C83-B4DD-E9C28AB760EE

Q36252668-402DF012-9E48-4665-AEF7-BABC3DE3D31D

Q36252668-4BD7B827-6F2A-44D6-97F6-8E84068854C4

Q36252668-4E5E8EAD-78E9-48F8-AF0B-0B2D1E0BA48E

P304

Q36252668-84F55124-4887-41E6-9A0B-572271D92D28

P31

Q36252668-854B58C5-E394-4ADE-BE64-6402917D7A60

P356

Q36252668-11827327-856B-40C8-9DCD-914ABF04EB63

P407

Q36252668-C53F8FF5-0DBB-4783-AF9E-9FB86A392DB1

P433

Q36252668-883386CF-FB00-4949-81ED-7B30C218FB26

P478

Q36252668-8DD0256C-2C31-4B98-8304-84AC9B3DE448

P577

Q36252668-AA6AFF9D-ACAE-4FD9-9088-C02883DBE653

P5875

Q36252668-E3C6408E-C023-44DE-98F2-C5D5BBC8E69C

P698

Q36252668-7E250875-E75F-4B1C-9D32-F143115A10D8

P921

Q36252668-A4A545CE-CDF4-49B9-9829-EF1CE57DA748

P932

Q36252668-F9C10574-0ABA-49A6-8C46-754304881029

P356

P1433

International Journal of Geriatric Psychiatry

P1476

The association of psychotropi ...... ectory of Alzheimer's disease.

@en

P2093

C Corcoran

http://www.w3.org/2001/XMLSchema#string

C G Lyketsos

http://www.w3.org/2001/XMLSchema#string

D Han

http://www.w3.org/2001/XMLSchema#string

G B Rattinger

http://www.w3.org/2001/XMLSchema#string

I H Zuckerman

http://www.w3.org/2001/XMLSchema#string

J C S Breitner

http://www.w3.org/2001/XMLSchema#string

J S Leoutsakos

http://www.w3.org/2001/XMLSchema#string

J T Tschanz

http://www.w3.org/2001/XMLSchema#string

K A Welsh-Bohmer

http://www.w3.org/2001/XMLSchema#string

M C Norton

http://www.w3.org/2001/XMLSchema#string

P2860

“Mini-mental state”

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study

The Clinical Dementia Rating (CDR): current version and scoring rules

Antipsychotics and cognitive decline in Alzheimer's disease: the LASER-Alzheimer's disease longitudinal study.

Use of antipsychotics among elderly nursing home residents with dementia in the US: an analysis of National Survey Data.

Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data.

Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes.

Implications of adult hippocampal neurogenesis in antidepressant action.

Sertraline for the treatment of depression in Alzheimer disease.

P304

1248-1257

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/GPS.3769

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221870838

http://www.w3.org/2001/XMLSchema#string

P698

22374884

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

3448859

http://www.w3.org/2001/XMLSchema#string